MedTrace Logo

Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes

NCT04365400 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 233

Last updated 2023-06-12

Study results available
· View outcomes & findings →

Summary

To assess the efficacy and safety of orally administered Epeleuton capsules versus placebo, in the treatment of adult patients with hypertriglyceridemia and type 2 diabetes

Conditions

Interventions

DRUG

DS102

DS102 Epeleuton capsules

DRUG

Placebo

Placebo capsules

Sponsors & Collaborators

  • Afimmune

    lead INDUSTRY

Principal Investigators

  • Markus Weissbach, MD · Afimmune

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-13
Primary Completion
2022-05-03
Completion
2022-05-03
FDA Drug
Yes

Countries

  • United States
  • Georgia
  • Germany
  • Israel
  • Latvia
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04365400 on ClinicalTrials.gov